Last reviewed · How we verify
Placebo for pirfenidone
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in Phase 3 trial for idiopathic pulmonary fibrosis (pirfenidone comparison).
At a glance
| Generic name | Placebo for pirfenidone |
|---|---|
| Sponsor | Douglas D. Fraser |
| Modality | Small molecule |
| Therapeutic area | Pulmonary Fibrosis |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. Any observed effects in placebo recipients are attributed to the placebo effect—psychological and physiological responses to the expectation of treatment rather than the drug itself. In this Phase 3 trial, placebo serves as the comparator arm to assess the true clinical benefit of pirfenidone.
Approved indications
- Control arm in Phase 3 trial for idiopathic pulmonary fibrosis (pirfenidone comparison)
Common side effects
Key clinical trials
- A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis (PHASE2)
- Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis (PHASE3)
- Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients (PHASE1)
- To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF (PHASE2)
- Effect of Pirfenidone on TA Fibrosis (PHASE4)
- Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study (PHASE3)
- PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients (PHASE2)
- Safety and Tolerability of Pirfenidone in Acute Pancreatitis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for pirfenidone CI brief — competitive landscape report
- Placebo for pirfenidone updates RSS · CI watch RSS
- Douglas D. Fraser portfolio CI